Factors associated with poor outcomes among adults hospitalised for influenza in France: A three-year prospective multicenter study by Loubet, Paul et al.
Factors associated with poor outcomes among adults
hospitalised for influenza in France: A three-year
prospective multicenter study
Paul Loubet, Nezha Samih-Lenzi, Florence Galtier, Philippe Vanhems, Pierre
Loulergue, Xavier Duval, Ste´phane Jouneau, De´borah Postil, Sylvie Rogez,
Martine Valette, et al.
To cite this version:
Paul Loubet, Nezha Samih-Lenzi, Florence Galtier, Philippe Vanhems, Pierre Loulergue, et
al.. Factors associated with poor outcomes among adults hospitalised for influenza in France:
A three-year prospective multicenter study. Journal of Clinical Virology, Elsevier, 2016, 79,
pp.68-73. <10.1016/j.jcv.2016.04.005>. <hal-01302409>
HAL Id: hal-01302409
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01302409
Submitted on 14 Apr 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 1 
Factors associated with poor outcomes among 
adults hospitalised for influenza in France: A 
three-year prospective multicenter study 
Paul Loubeta,b,c, Nezha Samih-Lenzid, Florence Galtiere, Philippe Vanhemsf,g, Pierre 
Loulerguea,c,d, Xavier Duvalh,i, Stéphane Jouneauj, Déborah Postilk, Sylvie Rogezl, 
Martine Valettem, Corinne Merlen, Corinne Régiso, Yolande Costah, Zineb Lesieurd, 
Pierre Tattevinp, Bruno Linam, Fabrice Carratq,r, Odile Launaya,b,c,d and the FLUVAC 
Study Group. 
a. Inserm, CIC 1417, Paris, France,  
b. Université Paris Descartes, Sorbonne Paris Cité, Paris, France 
c. Department of Infectious Diseases, CIC Cochin Pasteur, Cochin Broca Hôtel-Dieu hospital, 
Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France 
d. Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France 
e. CHRU de Montpellier, CIC 1411, Hôpital Saint-Eloi, Montpellier, France 
f. Service d’Hygiène, Epidémiologie et Prévention, Groupement Hospitalier Edouard Herriot, Lyon, 
France 
g. Emerging Pathogens Laboratory – Fondation Mérieux, Centre International de Recherche en 
Infectiologie (CIRI) Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, 21, Avenue Tony 
Garnier, Lyon 69007, France 
h. Inserm CIC 1425, Hôpital Bichat-Claude Bernard, APHP, Paris, France 
i. IAME UMR 1137 ; Univ Paris Diderot, Sorbonne Paris Cité, F-75019, Paris, France 
j. Centre Hospitalo-Universitaire de Rennes, Service de Pneumologie, IRSET UMR 1085, Université 
de Rennes 1, Rennes, France 
k. CHU Dupuytren, CIC 1435, Limoge Cedex, France 
l. CHU Dupuytren, Service Bactériologie, Virologie, Hygiène, Limoges Cedex, France 
m. CNR Virus Influenza, Hospices Civils de Lyon, Bron, University of Lyon, Lyon, France 
n. CHRU de Montpellier, Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Eloi, 
Montpellier, France; 
o. Université Lyon 1, Laboratoire de Biométrie et Biologie Evolutive, UMR CNRS 5558 
p. CHRU de Rennes, Service de Maladies Infectieuses et Tropicales, Rennes, France; 
q. Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d’Epidémiologie et de 
Santé Publique (IPLESP UMRS 1136), F75012, Paris, France 
r. Public health department, Hopital Saint-Antoine, APHP, Paris, France 
Corresponding author : 
Pr Odile LAUNAY  
Fédération d’infectiologie 
Groupe Hospitalier Cochin - Saint Vincent de Paul 
27 rue du Faubourg St Jacques 
75679 Paris Cedex 14, France 
Tel: +33 1 58 41 28 58 
Fax: +33 1 58 41 29 10 
Running Title: Severe influenza-associated hospitalizations in France 
Keywords: Influenza; Hospitalisation; Adults; Vaccination; Antiviral; Severe 
Length of the abstract: 249 words 
Length of the paper:  2 457 words 
 2 
Abstract  
Background. Influenza is an important cause of serious illness and death, 
particularly in elderly and high-risk groups. 
Objectives. Aim of this study was to identify factors associated with poor outcomes 
among adults hospitalized in France for laboratory-confirmed seasonal influenza. 
Study design. Patients hospitalized for influenza were identified in a prospective, 
multicenter study carried out in French hospitals during three consecutive influenza 
seasons (2012-2015). Influenza virus infection was confirmed by reverse 
transcription polymerase chain reaction. Sociodemographic and clinical variables 
were compared according to the virus type and subtype. Risk factors for 
complications, intensive care unit (ICU) admission and death were analyzed by 
backward stepwise logistic regression. 
Results. The study population consisted of 566 patients, of whom 56% were older 
than 65 years and 82% had underlying chronic illnesses. Type A influenza viruses 
infected 422 patients (75%), including subtype H3N2 in 239 patients (57%). The prior 
vaccine coverage rate was 38%. Complications occurred in 255 patients (45%), 
consisting mainly of pneumonia (n=143, 30%) and respiratory failure (n=116, 20%). 
Eighty-three patients (15%) were admitted to an ICU, and the in-hospital mortality 
rate was 4% (n=21). Sixty-six patients (12%) received oseltamivir. Age over 65 years 
was the only identified risk factor for complications. Risk factors for ICU admission 
were an absence of vaccination, no oseltamivir administration before admission, pre-
existing chronic respiratory disease, and current smoking. Age over 65 years and ICU 
admission were risk factors for death. 
Conclusions. Older individuals and patients with underlying conditions are most at 
risk of influenza complications. Vaccination and early oseltamivir administration, 
both of which are recommended for these patients, appear to reduce ICU admissions.  
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Background 
Influenza is an important cause of serious illness and death, particularly among 
adults over 65 years old and patients with chronic underlying conditions [1–4]. Each 
year, 5%–20% of the world population is infected by influenza viruses, and an 
estimated annual average of 36 000 deaths and 1 200 000 hospital admissions 
attributable to influenza virus infection occur in the United States [2,5]. Patients over 
65 years of age account for 54–70% of hospital admissions and 71–85% of deaths [6].   
Influenza is often under-diagnosed in acute-care hospital settings, owing to variable 
clinical presentations in adults [7–10], late hospital presentation for evaluation or 
care [11], and predominance of non-pulmonary diagnosis for admissions that may 
masked the influenza diagnosis [5]. Vaccination is the cornerstone of influenza 
prevention. Vaccine efficacy is abut 60% overall [12] but varies with age, underlying 
diseases/comorbidities, the predominant viral strain, and the considered outcome. 
Vaccination reduces the risk of pneumonia [13], hospitalization and death [14–16]. 
Early antiviral treatment is also recommended for patients at risk of complications 
[17–19].  
Objectives 
The aim of this study was to identify factors associated with poor outcomes among 
adult patients hospitalized for influenza in 6 French university hospitals participating 
in a multicenter, prospective, hospital-based epidemiological study carried out during 
three consecutive influenza seasons from 2012 to 2015. 
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Study design 
We studied cases of laboratory-confirmed influenza occurring during three successive 
seasons and identified by the FLUVAC study, a French prospective observational 
hospital-based study [20]. Briefly, we collected data on non-institutionalized adults 
(>18 years) hospitalized for at least 24 hours in one of the six participating hospitals 
(Cochin Hospital, Paris; Bichat Hospital, Paris; Rennes Hospital; Limoges Hospital; 
St. Eloi Hospital, Montpellier; Edouard Herriot Hospital, Lyon) for influenza-like-
illness (ILI), with symptom onset less than seven days prior to inclusion, through an 
active surveillance system composed of healthcare professionals trained to follow the 
FLUVAC study protocol. ILI was defined as a combination of the following three 
criteria: (i) sudden symptom onset, (ii) at least one of the following symptoms: fever 
(≥38°C), headache, myalgia or malaise, and (iii) at least one of the following 
respiratory symptoms: cough, sore throat, or shortness of breath (dyspnea) [21]. The 
“sudden” nature of symptom onset was a subjective concept left to the patients’ 
appreciation.  
Influenza virus infection was detected by applying the reverse transcription-
polymerase chain reaction (RT-PCR) to nasopharyngeal swabs (bronchoalveolar 
lavage fluid or tracheal aspirate for ICU patients). The FLUVAC study 
(clinicaltrials.gov NCT02027233) respected Good Epidemiological and Clinical 
Practices in clinical research and the Declaration of Helsinki, and was approved by 
regional ethics committees.  
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Study population and data collection 
 
We included all laboratory-confirmed (RT-PCR-positive) cases of influenza identified 
during three consecutive influenza seasons (2012/2013, 2013/2014 and 2014/2015) 
among the 1452 patients included in the FLUVAC study. 
We collected data on demographic characteristics, chronic underlying diseases, 
hospital admissions in the previous 12 months, smoking status, influenza vaccination 
in the current season and previous two seasons, the hospitalization ward, and the 
following characteristics of the current influenza episode: clinical presentation and 
outcome, including date of onset, hospitalization and treatment; length of hospital 
stay, treatment, and complications. 
Data sources included the hospitals’ medical records, interviews with the patients, 
families and regular physicians; vaccination registries, and laboratory databases. 
Vaccination status was ascertained during interviews with the patients and their 
families, and was confirmed from pharmacy records. 
Laboratory data  
The samples were initially tested in the virology laboratories of the participating 
hospitals by in-house real-time influenza A & B PCR after manual nucleic acid 
extraction. Amplification was performed in a ABI 7500 thermocycler. All samples 
were then sent to the French National Influenza Reference Center (CNR-Lyon) for 
confirmation by RT-PCR. Samples positive in the reference center were molecularly 
subtyped for viruses known to be circulating at the time namely type A (subtypes 
H1N1pdm09 and H3N2) and type B. Molecular subtyping was able to determine the 
H subtype for influenza A and the lineage for influenza B. Subtyping failed in some 
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cases because of low viral load and samples were thus classified as “unidentifiable”. 
In case of a discrepancy with local results, the reference center results were 
considered final. Only the reference center results were taken into account in the 
analyses. 
Statistical analysis  
Results were expressed as means and standard deviation (SD) or medians and 
interquartile range (IQR) for continuous variables, and N (%) for categorical 
variables.  Age was considered as a binary variable (< and ≥ 65 years, the age at which 
influenza vaccine is recommended in France). 
The Wilcoxon rank sum test or Fisher’s exact test was used, as appropriate, for 
univariable comparisons. To take into account subgroup comparisons, a p value of 
0.025 or less was considered statistically significant. Missing data for each variable 
were excluded from the denominator. 
Factors associated with death, complications and ICU admission were identified in a 
backward stepwise logistic regression model that included all variables with a p value 
<0.20 in univariate analysis and was adjusted for potential confounders, including 
“age”, “sex”, “influenza season”, “time from symptom onset to admission” and 
“chronic respiratory disease”, as appropriate. Results are expressed as odds ratios 
(OR) and adjusted odds ratios (aOR) with their 95% confidence intervals (95%CI). In 
the final model, a p value of 0.05 or less was considered statistically significant. 
All analyses were performed using Stata software (V12, © Copyright 1996–2014 
StataCorpLPt). 
 
Results 
Patient characteristics (Table 1) 
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A total of 566 cases of laboratory-confirmed influenza were diagnosed during the 
study period, comprising respectively 162, 112 and 292 cases during the 2012/2013, 
2013/2014 and 2014/2015 seasons. Median age was 67 years (IQR, 51-81), 316 
patients (56%) were older than 65 years, and 296 patients (52%) were men. Chronic 
underlying diseases were present in 462 patients (82%), and consisted mainly of 
chronic respiratory diseases (n= 230, 40% of all patients), chronic heart disease 
(n=224, 40%) and diabetes (n=140, 25%). Twelve women were pregnant (influenza 
A/H1N1 in 7 cases, influenza B in 5 cases). Two hundred forty patients (40%) had 
been hospitalized in the previous year, and the average number of admissions among 
these 240 patients was 2.2 (SD 2.6). The prior vaccination rate was 38% (215/566). 
According to French recommendations (www.sante.gouv.fr/calendrier-
vaccinal.html), 472 patients (88%) should have been vaccinated, but this was the case 
of only 197 (42%) of these patients. The vaccination rate was 19% (n=47) among 
patients under 65 years old and 53% (n=168) among patients aged 65 years or more 
(p=0.001). 
Table 1. Characteristics, clinical presentation and outcomes of the 566 influenza 
patients diagnosed between 2012 and 2015 in six French University hospitals 
 n % 
Baseline characteristics   
  Men 296 52% 
  Median age, years (IQR) 67 (51-81) - 
  Age ≥65 years 316 56% 
  Median BMI, kg/m2 (IQR) 25 (22-28) - 
  BMI ≥ 40 15 3% 
  Chronic diseases (indicating Influenza vaccination) 462 82% 
       Chronic respiratory disease 230 40% 
       Chronic heart disease 224 40% 
       Diabetes 140  25% 
       Chronic renal failure 66 12% 
       Immunosuppression 56 8% 
       Others 237 42% 
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  Pregnancy  12 2%* 
  Current smokers 266 48% 
  Indication for vaccination 472 88% 
  Vaccination in current season 215 38% 
  ICU admission 83 15% 
  Hospitalization in the previous 12 months 240 42% 
  Mean number of hospitalizations in the previous 12 months (SD)    
among patients hospitalized at least once 
2.2 (2.6) - 
Clinical presentation   
Median time from symptom onset to hospitalization, days (IQR) 2 (1-3)  
       Fever (≥38°C) 504 89% 
       Cough 487 86% 
       Dyspnea 387 69% 
       Sudden symptom onset 289 51% 
       Weakness/malaise 164 29% 
       Headache 154 28% 
       Myalgia 128 23% 
Outcome and treatment   
  At least one complication during the hospital stay 255 45% 
       Pneumonia 143/473 30% 
       Respiratory failure 116/473 20% 
       Acute heart failure 67/473 12% 
       Acute respiratory distress syndrome (ARDS) 58/473 10% 
  Antiviral use 66 12% 
  Median length of stay, days (IQR)  6 (3-10) - 
  Death 21 4% 
IQR: interquartile range   
* Pregnant women represented 2% of all patients and 4% of the 270 women. 
 
Clinical presentation (Table 1) 
Median time from symptom onset to hospitalization was 2 days (IQR, 1-3). The most 
frequent symptoms were fever and cough, present in respectively 504 (89%) and 487 
(86%) cases. Dyspnea was reported by 387 patients (69%). Other symptoms were 
each present in 20% to 30% of patients. Sudden symptom onset was reported by 289 
patients (51%). After adjustment for the influenza season and vaccination status, 
older age was associated with less intense symptoms. In particular, fever, headache 
and myalgia were less common in patients over 65 (OR 0.53; 95%CI 0.29-0.96, 
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p=0.036; OR 0.40; 95%CI 0.26-0.61, p=0.001; and OR 0.39; 95%CI 0.25-
0.62,p=0.001, respectively). ICU admission was necessary in 83 cases (15%).  
Outcome and treatment (Table 1) 
A total of 473 medical complications related to influenza occurred among 255 
patients (45%) during their hospital stay. Pneumonia (143 episodes, 30% of 
complications), respiratory failure (116, 20%), heart failure (67, 12%) and ARDS (58, 
10%) were the most frequent.  
Oseltamivir was prescribed to 66 patients (12%), 75% of whom had a chronic 
underlying condition. Oseltamivir therapy was initiated less than 48 h after symptom 
onset in 88% of cases. 
The median length of hospital stay was 6 days (IQR 3-10).  
Twenty-one patients (4%) died during the hospital stay. All of them had at least one 
chronic underlying disease and 19 (90%) were over 65 years old. The median time 
from admission to death was 12 days (IQR 7–20). 
Virologic data (Table 2) 
Influenza virus type A was detected in 422 patients (75%); it was subtype H1N1 in 163 
cases (39%), H3N2 in 239 cases (57%), and “unidentifiable” in 20 cases (4%). Type B 
was detected in 144 patients (25%), and was subtype Yamagata, Victoria and 
“unidentifiable” in respectively 115 (80%), 9 (6%) and 20 (14%) cases.  
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Table 2. Virologic data for 566 cases of influenza diagnosed between 2012 and 
2015 in 6 French University hospitals  
  2012/2013 2013/2014 2014/2015 Total 
Influenza cases 162 112 292 566 
Type A 80 (49%) 109 (97%) 233 (80%) 422 (75%) 
     H1N1 30 59 74 163 
     H3N2 50 44 145 239 
     Unidentifiable 0 6 14 20 
Type B 82 (51%) 3 (3%) 59 (20%) 144 (25%) 
     Victoria 7 0 2 9 
     Yamagata 64 3 48 115 
     Unidentifiable 11 0 9 20 
Considered viral circulation (1) A(H1N1)pdm09 
+ B (Yamagata) 
A(H1N1)pdm09 
+ A(H3N2) 
A(H3N2)** - 
 
(1) From the Flunet database (http://www.who.int/influenza/gisrs_laboratory/flunet/); Indicate 
the viral dominant type or subtype; 
** circulating strains differed from vaccine strains 
 
Compared to patients with type B influenza, patients with type A influenza were more 
likely to have a chronic respiratory disease (44% vs 31%, p=0.01), dyspnea (72% vs 
59%, p=0.007) and sudden symptom onset (56% vs 41%, p=0.003). (Table 3) 
Compared to patients with H1N1 influenza, patients with H3N2 influenza were 
significantly older (73 years, IQR 58-83 vs 60 years, IQR 47-74; p=0.001), more likely 
to have an underlying chronic respiratory disease (45% vs 34%, p=0.02) or diabetes 
(30% vs 18%, p=0.01), and more likely to have dyspnea (78% vs 67%, p=0.02) and 
ARDS (15% vs 8%, p=0.02). (Table 3) 
The vaccine coverage rate was higher among patients with H3N2 influenza (45%) 
than among those with H1N1 influenza (30%, p=0.003), in each of the three seasons 
(Table 3). 
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Factors influencing outcome 
The median hospital stay was longer among patients with influenza A than those with 
influenza B (5 days, IQR 2-9 vs 6 days, IQR 3-10; p=0.02) but was similar across A 
subtypes (Table 3). Vaccination status did not influence the length of stay. The 
patients who died had type A/H3N2 (n=10), A/H1N1 (n=4), A/unidentifiable (n=1), 
or B (n=6) influenza. The mortality rate did not differ according to the virus type or 
subtype, vaccination status, or the influenza season. The virus types and subtypes did 
not influence these outcomes, and neither did the time from symptom onset to 
hospitalization. 
Multivariate analysis  
After adjustment for age, sex, the influenza season and time from symptom onset to 
admission, the risk of ICU admission was increased by the absence of antiviral 
therapy, no prior influenza vaccination, current smoking, and chronic respiratory 
disease (all p<0.05) (Table 4).  
Table 4. Risk factors for ICU admission among 566 patients hospitalized for 
influenza from 2012 to 2015, as identified in the final logistic regression model 
 aOR (95%CI) p value 
Age ≥65 years 0.77 (0.45-1.30) 0.33 
Female gender 0.79 (0.47-1.32) 0.36 
Influenza season   
   2012/2013 1 (Ref.) - 
   2013/2014 1.12 (0.50-2.48) 0.78 
   2014/2015 1.73 (0.92-3.24) 0.09 
Time between symptom onset and admission* 1.1 (0.89-1.15) 0.88 
Vaccination in current season 0.50 (0.28-0.90) 0.02 
Oseltamivir use 0.35 (0.19-0.66) 0.01 
Current smoking 1.82 (1.06-3.12) 0.04 
Chronic respiratory disease 1.66 (1.01-2.77) 0.05 
The outcome analyzed was ICU admission during the initial hospital stay.  
The model was adjusted for “sex”, “age”, “influenza season” and “time from symptom onset to 
admission”. 
*Continuous variable 
aOR: adjusted odds ratio; 95%CI: 95% confidence interval; Ref.: Reference 
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After adjustment for sex, the influenza season, time from symptom onset to 
admission, and chronic respiratory disease, the only risk factor for clinical 
complications was age over 65 years (OR 1.72; 95%CI 1.22-2.44,p=0.002). After the 
same adjustment, age over 65 years (OR 10.31; 95%CI 2.31-45.90, p=0.002) and ICU 
admission (OR 5.37; 95%CI 2.0-14.56, p=0.001) were both associated with the risk of 
death.  
Discussion 
This prospective multicenter study involved 566 patients with laboratory-
confirmed influenza admitted to 6 hospitals during three winter seasons, from 2012 
to 2015. Most of the patients were over 65 years old and had at least one underlying 
disease. Nearly half the patients developed influenza complications during their 
hospital stay. Antiviral therapy and vaccination had a preventive effect on ICU 
admission.  
Older age and chronic underlying conditions are known risk factors for severe 
influenza. In a Spanish multicenter study comparing influenza inpatients and 
outpatients in 2010/2011, Castilla et al. found that hospitalized patients were older 
and had more chronic diseases [22].  
We found that patients over 65 years old tended to have atypical symptoms, 
confirming previous reports [23]. Babcock et al. and Walsh et al., studying 
respectively 207 and 56 elderly patients hospitalized with influenza, found that cough 
and fever were the most common symptoms, while fever was absent in around 30% of 
cases [10,24]. We found a high rate of complications, ICU admission and death, 
confirming the severity of influenza in older patients with underlying conditions 
[11,25].  
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Vaccination rates varied according to the influenza virus type and subtype, 
underlining differences in vaccine efficacy between these groups, owing mainly to 
differences in age and underlying conditions. In particular, the vaccination rate was 
higher among patients with H3N2 infection, suggesting that vaccination was less 
effective in this subgroup. This may be due partly to immune senescence, as these 
patients were significantly older than patients with H1N1 infection, and partly to 
vaccine mismatch in the northern hemisphere during the 2014-2015 season, due to 
A/H3N2 antigenic drift from the vaccine virus, while subtype A/H3N2 accounted for 
more than 70% of all subtyped influenza A viruses [26].  
Vaccination of elderly persons prevents only 30-40% of influenza cases, and its 
impact on the severity of influenza is controversial [27,28]. However, many studies 
have shown a beneficial impact of vaccination on hospitalization, complications and 
death [22,29–34]. More recently, Grijalva et al. reported that vaccination reduced 
hospitalizations for influenza-associated pneumonia by 56% in a large US case-
control study [13]. 
We found no impact of vaccination on mortality, whereas ICU admission was less 
frequent among vaccinees, underlining the importance of vaccination for at-risk 
patients.  
In a recent study of 5614 patients hospitalized for laboratory-confirmed influenza, 
selected from a US population-based influenza-related hospitalization surveillance 
system during the 2012/2013 season, Arriola et al. found that 71% of patients were 
over 65 years old, 91% had medical conditions, 14% were admitted to an ICU, and 2% 
died. Fifty-five percent of the patients had been vaccinated. No association was found 
between vaccination status and ICU admission, death, pneumonia, or the length of 
hospital or ICU stay. However, after restricting the analysis to patients treated with 
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antiviral drugs and matching them for a vaccination propensity score, they found that 
the length of ICU stay was reduced by a factor of 0.6 (95%CI 0.4-0.8) among 
vaccinated 50- to 64-year-olds compared to their unvaccinated counterparts. A 
similar but non significant trend was found among patients aged from 65 to 74 [25]. 
Castilla et al. found that vaccination protected against severe influenza, defined as 
ICU admission or in-hospital death, and suggested that vaccination might be more 
effective in preventing severe than mild illness [22]. By comparison with the latter 
study, antiviral use in our patients was very low, probably owing to a lack of 
diagnostic confirmation during the recommended period of antiviral introduction 
(<48h after symptom onset). We found that antiviral use was associated with a lower 
risk of ICU admission among patients with underlying respiratory diseases, but not 
with lower mortality. These results are in agreement with several studies showing a 
reduction in mortality and complications among patients with severe influenza who 
received antivirals [19,35–38].   
The strengths of this study include the large number of patients hospitalized 
for influenza, the multicenter, prospective design, uniform patient screening in the 
different centers, diagnostic confirmation in an influenza reference center, the 
lengthy study period spanning three consecutive influenza seasons, and precise 
documentation of influenza virus types and subtypes. Several limitations must also be 
acknowledged. First, as all the participating centers were teaching hospitals, the 
proportion of patients with underlying diseases may have been higher than in the 
general population, owing to a referral bias. Second, although the sample was large, 
the study was probably underpowered to identify a moderate impact of antivirals and 
vaccination on mortality. Finally, a small number of samples were misclassified by 
on-site tests, 9 false positives and 25 false negatives being identified by centralized 
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testing in the reference center. This should be taken into account when considering 
the way patients were treated. 
In conclusion, most patients hospitalized for severe influenza in France are elderly 
individuals with underlying conditions, leading to a high risk of complications and 
ICU admission. It is noteworthy that almost all the patients in this study qualified for 
influenza vaccination according to national guidelines. As recommended, antiviral 
treatment should be used in the first 48h after ‘flu-like symptom onset in order to 
reduce the duration of required medical care. 
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